8-K: Oaktree III Life Sciences Appoints Dr. David Berry to Board

Oaktree Acquisition Corp. III Life Sciences announced the appointment of Dr. David A. Berry, a seasoned life sciences executive, as an independent director to its board.

Summary

• Oaktree Acquisition Corp. III Life Sciences appointed Dr. David A. Berry as an independent director, effective October 17, 2025.
• Dr. Berry will serve as a Class II director and join the audit, nominating, and compensation committees.
• The board determined Dr. Berry to be an independent director under Nasdaq listing standards and Rule 10A-3 of the Exchange Act.
• Dr. Berry brings extensive experience from Averin Capital, Flagship Pioneering, and leadership roles at Valo Health, Omega Therapeutics, Seres Therapeutics, Axcella Health, and Evelo Biosciences.
• He holds an M.D. from Harvard Medical School and Ph.D. and B.S. from the Massachusetts Institute of Technology.
• Dr. Berry will not receive compensation for his director services but is expected to have an opportunity for a non-controlling minority investment in Oaktree Acquisition Holdings III LS, LLC, similar to other independent directors.
• He will also enter into standard Letter and Indemnity Agreements with the Company.

Sentiment

Score: 8

Explanation: The appointment of a highly qualified and experienced independent director with a strong background in life sciences and venture capital is a positive development for corporate governance and strategic guidance, indicating a strengthening of the board's capabilities. The lack of direct compensation is offset by the investment opportunity, which aligns interests.

Positives

• The appointment of a highly experienced independent director with a strong background in life sciences, venture capital, and company leadership is a significant asset.
• Dr. Berry's expertise in founding and leading multiple biotech companies (Valo Health, Seres Therapeutics, Axcella Health, Evelo Biosciences) and his roles at Flagship Pioneering and Averin Capital will provide valuable strategic guidance.
• His appointment to the audit, nominating, and compensation committees strengthens corporate governance and oversight.
• The board's determination of his independence aligns with regulatory and exchange standards, ensuring objective decision-making.

Future Outlook

The company expects Dr. Berry to be offered an opportunity to make a non-controlling minority investment in Oaktree Acquisition Holdings III LS, LLC, consistent with other independent directors. He is also expected to enter into standard Letter and Indemnity Agreements.

Management Comments

• Dr. Berry will serve as a Class II director until his successor is duly appointed and qualified or until his earlier resignation, removal or other cessation as a director.
• The Board determined that Dr. Berry qualified as an independent director under the listing standard of the Nasdaq Stock Market and as defined by Rule 10A-3 under the Exchange Act of 1934, as amended.
• Dr. Berry will not be compensated by the Company for his services as a director of the Company.
• It is expected that Dr. Berry will be given an opportunity to make an investment for a non-controlling minority position in Oaktree Acquisition Holdings III LS, LLC, similarly to the other independent directors serving on the Board.
• Dr. Berry is expected to enter into a Letter Agreement and Indemnity Agreement with the Company on the same terms as the Letter Agreements and Indemnity Agreements entered into by the other directors and officers of the Company at the time of the Company’s initial public offering.

Industry Context

The appointment of a director with extensive experience in life sciences, venture capital, and biotech company leadership is a common practice for SPACs like Oaktree Acquisition Corp. III Life Sciences, especially those focused on a specific sector. Such appointments aim to leverage industry expertise for identifying and executing successful de-SPAC transactions, which is crucial in the competitive life sciences M&A landscape.

Comparison to Industry Standards

• Dr. Berry's background, including his roles at Flagship Pioneering and Averin Capital, aligns with the industry standard for SPACs seeking directors with deep domain expertise and a strong network in their target sector. For example, other life sciences SPACs often appoint directors with similar venture capital or operational leadership experience from firms like ARCH Venture Partners or Third Rock Ventures.
• His experience as CEO and board member for multiple publicly traded biotech companies (e.g., Omega Therapeutics, Seres Therapeutics, Axcella Health, Evelo Biosciences) provides direct operational and governance experience highly valued in the life sciences industry, comparable to directors on boards of established biotech firms.
• The appointment to key committees (audit, nominating, compensation) is standard practice for independent directors, ensuring robust corporate governance in line with Nasdaq and SEC requirements.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** The appointment of a highly experienced director with a strong track record in the life sciences industry is likely to be viewed positively, potentially increasing confidence in the company's ability to identify and execute a successful business combination. His expertise could lead to better strategic decisions and value creation.
• **Management:** Dr. Berry's extensive experience and network could provide valuable guidance and support to the executive team, particularly in navigating the complexities of the life sciences sector and potential merger targets.
• **Future Merger Targets:** The enhanced board expertise could make Oaktree Acquisition Corp. III Life Sciences a more attractive partner for potential target companies seeking a SPAC with strong strategic leadership.

Next Steps

• Dr. Berry will enter into a Letter Agreement and Indemnity Agreement with the Company.
• Dr. Berry is expected to be given an opportunity to make a non-controlling minority investment in Oaktree Acquisition Holdings III LS, LLC.

Key Dates

Recommendation

The appointment of Dr. David A. Berry is a positive development, bringing significant industry expertise and strengthening corporate governance. This move is expected for a SPAC aiming to execute a successful business combination in the life sciences sector. While positive, it is a standard governance enhancement rather than a transformative event that would warrant a 'buy' recommendation on its own. Investors should 'hold' as they await further developments regarding a potential merger target, with this appointment reinforcing the company's foundational strength.

Keywords

Oaktree Acquisition Corp. III Life Sciences, David A. Berry, Board of Directors, Independent Director, Corporate Governance, Life Sciences, Biotechnology, SPAC, Nasdaq, Audit Committee, Nominating Committee, Compensation Committee